Abstract
INTRODUCTION
Since the first discovery of BK polyomavirus (BKV) isolated from the urine of a renal allograft recipient with ureteric obstruction in 1971 [1] , BKV infection has emerged as an important cause of renal allograft dysfunction. In the modern era, with the use of more potent immuno suppressive agents, BKV nephropathy (BKVN) has resulted in a significant rate of graft loss [2] . Seroprevalence of BKV in immunocompetent adults ranges from 65% to 90% and BKV remains latent pre dominately in the urinary tract [3] . Immunosuppression, inflammation and insufficient anti-viral immune responses play an integral role in the reactivation and replication of BKV and progression to BKVN in renal transplant recipients [4] . Dendritic cell deficiency, seronegativity for BKV and impaired BKV-specific T-cell response are found to be associated with BK viraemia [58] . Other possible risk factors for BK viraemia include a long cold ischaemia time (CIT) [9] , acute rejection [10, 11] , placement of a ureteric stent [12, 13] , human leukocyte antigen (HLA) mismatch [11, 14] , lymphocytedepleting agents [1518] , tacrolimus [19, 20] and steroids [16, 19, 20] . Given the complexity in the pathogenesis of BKVN, the intensity of immunosuppression may not be solely responsible for the development of BKVN and it may not be appropriate to generalise these predisposing risk factors in all renal transplant recipients. However, as the immunosuppressive burden appears a significant risk factor for the development of BK polyomavirus, it is possible that the immunosuppression regimen used accounts at least in part for the substantial variation in the prevalence of BK viruria (30%62%), BK viraemia (11.5%20%) and BKVN (1%10%) among transplant centres [10, 12, 21, 22] . No effective pharmacological treatment has con sistently emerged for the treatment of BKV infection apart from a reduction of immunosuppressants [23, 24] . Many investigators have recommended screening BK viraemia and preemptive reduction in immunosuppressants as a strategy to preserve graft function and reduce the risk of BKVN occurring [2528] . However, a screening programme may not be suitable in a transplant centre with a low rate of BVKN [29] . We conducted a retrospective review of renal tran splant recipients from our region, where no lymphocyte depleting induction treatment is used and the pre dominant calcineurin inhibitor utilised is Ciclosporin, to determine the incidence of BKVN and/or BK viraemia and to evaluate the characteristics that are potentially associated with the development of BKVN and related treatment outcome. Testing for serum BKV viral load is performed at a single laboratory, LabPlus™, in the Auckland region. The laboratory does not routinely perform BKV viral load in urine samples, due to the high prevalence of positive BK viruria in renal transplant recipients. Recipients are considered to have BK viraemia for any level of viral load. Testing for serum creatinine is performed at both hospital and community laboratories in the Auckland region. Estimated glomerular filtration rate (eGFR) was calculated using the CKDEPI equation [30] . The recipients' renal biopsies performed in the Auckland region were processed and interpreted at a single laboratory: LabPlus™.
MATERIALS AND METHODS

Patients
BKV surveillance
There is no formal screening programme among the three renal units in the Auckland region. One unit rou tinely screened for BKV from the year 2012. One of these hospitals trialled screening for BKV in 2009, but halted this strategy due to cost, and BK viral load (BKVL) test is performed only if there is a biopsy-proven BKVN. The third unit checks for BKV if there is a clinical indication or a biopsyproven BKVN.
Immunosuppression protocol
Basiliximab was routinely used for induction from August 2010. All male recipients were given Ciclosporin as their maintenance calcineurin inhibitor, but female recipients were given a choice of either Tacrolimus or Ciclosporin. The tacrolimus trough concentration in each recipient was kept between 10 to 15 µg/L for the first 2 mo after transplant, and then the target concentration was kept between 5 to 10 µg/L. The Ciclosporin (2 h post dose) target concentration was 1700 µg/L for the first month after transplant and 1500 µg/L for the second month. The target concentration was then gradually reduced to equal to or less than 800 µg/L after 12 mo of transplantation. Every recipient received Mycophenolate mofetil (MMF) 1 g twice daily if on Ciclosporin or 750 mg twice daily if on Tacrolimus. Concentration monitoring for MMF is not routinely performed. All recipients received Methylprednisolone 1 g at induction followed by prednisone as maintenance. The prednisone dose was 30 mg daily for all recipients and it was tapered down to 7.5 mg daily or lower at months 4 posttransplant.
Acute rejection treatment protocol
Recipients who have acute rejection Banff grade Ⅰ receive 
Renal transplant biopsy protocol
RESULTS
Description of the study population
Four hundred and twenty-eight patients underwent renal transplantation between January 2006 and December 2012. After excluding 194 patients from outside of the Auckland region and 8 patients who died or developed primary graft failure at one month after transplant, 226 were included in the study (Figure 1 ).
Seventysix recipients were tested for BKV (33.6%) at any point in time over the study period. Twenty-eight patients of 76 tested patients had BK viraemia (36.8%). Twenty of these 28 patients were managed with a reduction of their immunosuppressants; by reducing or stopping MMF and maintaining Tacrolimus trough concentration and Ciclosporin trough concentration between 46 µg/L and 100150 µg/L, respectively, depending on BKVLs' responses. Seven patients received Leflunomide concurrently; one BKVN recipient was given additional Ciprofloxacin as the BKVL failed to decline despite reducing immunosuppressants, and another BKVN recipient also received Ciprofloxacin and subsequently intravenous Immunoglobulin due to persistent high level of BK virae mia, worsening graft dysfunction and a repeat graft biopsy showed features of acute rejection in addition to BKVN. The remaining 8 BK viraemic recipients did not have a reduction of immunosuppressants due to low viral loads (all less than 1250 copies/mL).
Of these 28 patients, 16 patients had transplant biopsies for renal allograft dysfunction. Nine patients had biopsyproven BKV nephropathy equivalent to an incidence of 11.8% (95%CI: 5.6%21.3%) of the cohort tested for BKV viral load (9/76) or 4.0% (95%CI: 1.8%7.4%) of the entire cohort (9/226). Eight of these nine patients were tested for BKVLs after their transplant biopsies diagnosed BKVN. The other patient with BKVN had the transplant biopsy and serum BKVL requested concurrently as part of investigation of graft dysfunction. Three (33.3%) of the recipients with BKVN did not have acute rejection prior to the diagnosis of BKVN. The other 6 recipients (66.7%) had at least one episode of biopsy proven acute rejection requiring a pulse methy lprednisolone course prior to the development of BKVN. Ten of the 19 recipients (53.7%) with BK viraemia did not have acute rejection prior to the diagnosis of BK viraemia and the others (47.3%) had at least one acute rejection prior.
Associations with BKV nephropathy
When comparing features between recipients with BKVN and without BKVN, we found that BKVN was more common in Māori, Pacific Islanders and Asians than in Europeans (European 1.5%% vs Asian 9.3% vs Māori and Pacific Islanders 7.4%, P = 0.038). The renal allografts of the recipients that developed BKVN were all from deceased donors (P = 0.005). The BKVN group had a longer CIT (median 19 h vs 7 h, P = 0.001). The group was also more likely to have at least 1 episode of acute rejection at any time point, though it was not statistically significant (P = 0.069). There was no significant difference observed in age, gender, comorbidity, dialysis vintage, HLA mismatch, Tacrolimus, Basiliximab induction, or use of lymphocytedepleting agents for acute rejection between the positive (+) BKVN and negative () BKVN groups ( Table 1) .
Comparison of recipients with BK viraemia only and recipients with BKVN
There was no statistical difference in ethnicity, acute rejection at any time point and other demographics when comparing the BKVN group and the (+) BKV group (recipients with only BK viraemia and no biopsyproven BKVN). The (+) BKV group had fewer deceased donors (47.4%, P = 0.01) and shorter CIT (median 5.4 h, P < 0.0001) than patients who developed BKV nephropathy. BK viraemic recipients (47.4%) and recipients with BKVN We included only the variables that had P value < 0.1 in a multivariable model. Ethnicity was not found to be significant, and Longer CIT was the only risk factor for BKVN (HR = 1.18, 95%CI: 1.051.39, P = 0.009).
Risk factors for BKVN
Effect of BKVN and BK viraemia on renal allograft function
Renal allograft function in the BKVN group was signi ficantly lower comparing with those in the other BKV status groups (P = 0.015), and the median graft function of the recipients who were never checked for BK viraemia was similar to those with and without BK viraemia using the nonparametric KruskalWallist test (P = 0.374) (Figure 2 ). After controlling for those factors (age at transplant, comorbidity, donor source, HLA mismatch, acute rejection, Basiliximab induction, calcineurin inhibitor and eGFR at 1 mo after transplant) that could potentially affect graft function, the mean eGFR of the recipients with BKVN (taken just before the censored date or before recipients were transferred, but those who developed graft failure were not included) was still 17. One of the 9 recipients (11.1%) with BKVN had graft failure compared to 8 (3.7%) of those without, but there was no statistical difference found using a logrank test in the KaplanMeier survival analysis (Plogrank = 0.283) (Figure 3) . Similarly, no difference was found between those with known and unknown BKV status (0.92 for positive BKV and BKVN, 0.90 for negative BKV, and 0.92 for unknown BKV status, Plogrank = 0.568) (Figure 4 ).
Outcome of management of BKVN and BK viraemia
For those diagnosed with BKVN, BKVLs were undetectable in 4 recipients and the BKVL was less than 625 copies/mL in one recipient at the time of censoring. The other 3 patients still had persistent BK viraemia but viral loads were declining at the end of study period (Table 3) . One patient developed graft failure due to BKVN, but it is important to note that this recipient's graft function was poor prior to the diagnosis of BKVN (eGFR 23-27 mL/min per 1.73 m 2 ) with no clear explanation despite 4 graft biopsies that did not show any significant abnormality. BKVLs of the recipients with BK viraemia were either undetectable or declining during the study period. None of these 19 patients, including six of them with BKVLs more than 10 4 copies/mL, progressed to BKVN over the study period. Of the patients who had a reduction in immuno suppression none of the 11 patients with BK viraemia had acute rejection, while two of the 9 recipients with BKVN developed an acute T-cell mediated rejection grade 1B at 30 mo and 2 mo after their immunosuppressive therapy was reduced. The acute rejections were successfully treated with intravenous pulse methylprednisolone, and their calcineurin inhibitors were already switched to Tacrolimus from previous acute rejection prior to the diagnosis of BKVN.
DISCUSSION
This retrospective study has demonstrated that only one patient had graft failure due to BKVN in our cohort of patients. We identified 28 patients with BKV infection with a rate of 36.8% in the cohort that was screened. However, this has likely overestimated the incidence as 150 patients (66.4%) were not tested for BK viraemia. When considering the entire cohort the rate of BKV was 12.4% (28 of 226). The incidence of biopsy proven BKVN was 11.8% (9/76). It is important to note that it is unlikely that any patient with clinically significant BKV did not undergo testing due to the regional protocol to perform renal biopsy. However, it is possible that early BKVN could be missed by renal biopsy due to its focal nature [25] . Using the overall cohort we noted an incidence of 4.0% (9/226) which is comparable to that of other transplant centres with an active BKV screening programmes (0.8% to 6.4%) [11, 2628, 3133] . A long CIT was identified as a potential risk factor for BKVN in our study, and is known to cause severe ischaemiareperfusion injury resulting in intragraft inflammation, which in turn is found to stimulate BK polyomavirus DNA replication [34, 35] . Acute rejection results in tubulointerstitial inflammation and typically leads to also an increased burden of immunosuppression. How ever, interestingly in our cohort, acute rejection was not found to be a risk factor for progressing to BKVN. Although others have demonstrated an association be tween Tacrolimus use and BKVN, Tacrolimus was not found to be associated with BKVN in our cohort. Despite lymphocytedepleting agents were used for severe acute rejection episodes in this cohort, our analysis did not demonstrate more recipients with BK viraemia and BKVN. Other studies have also failed to show any correlation between lymphocytedepleting agents given at induction and BKV infection [26, 28] . Because of the difficulty in predicting BKVN in transplant recipients, a latent period from BK viraemia to the development of BKVN, and possible sampling errors in diagnosing early BKVN due to its focal nature [25] , screening of the blood or urine for BKV infection and preemptive reduction of immunosuppressants when BKV is detected have been shown to reduce, the risk of the development of BKVN (0.8%1.3%) [27, 28, 32, 33] . Interestingly, some centres report that despite having a BKV screening programme in the literature, their incidence of BKVN is greater than that seen in our cohort (4.2%6.4%) [11, 26, 31] , This includes one centre that screened for decoys cells in urine fortnightly for the first 3 mo, then at 6 and 12 mo and yearly after transplant [31] . It appears that frequent monthly BKV monitoring is essential in early detection of BK viraemia and intervention resulting in the lower incidences of BKVN described in the abovementioned studies, with one centre that performed a cheaper urine cytology screening fortnightly from 0 to 3 mo after trans plant, monthly from 3 to 6 mo and then every 2 mo from 6 to 12 mo [33] . Because all patients with a > 20% decline in renal function undergo routine biopsy and all patients undergo a protocol biopsy at 3 mo after transplantation in our study cohort, we postulate that a large proportion (66.4%) of our cohort with unknown BKV status had no episodes of graft dysfunction due to BKVN. Bohl and his coinves tigators looked at other studies and commented that BKVLs exceeding 10 4 copies/mL only have a positive predictive value of 50%85% for diagnosing BKVN [36] . BKVLs that are less than 10 4 copies/mL do not require intervention [28, 37] . This is reflected not only on the recipients who never had any BKVL tests, but also on the eight patients with low BKVLs who did not progress to BKVN even without a reduction of immunosuppressants and further BKV monitoring.
BKVN impacted on graft function; one patient lost their allograft and the other eight patients had a mean eGFR more than over 18 mL/min worse than patients without BKVN. This finding of poorer graft function from BKVN is also found in a prospective study that adopted a rigorous monthly screening programme the mean eGFR of recipients with BKVN (39.0 ± 14.3 mL/min per 1.73 m 2 ) was lower than that of those without BKVN (52.3 ± 19.9 mL/min per 1.73 m 2 ), though there was no graft failure due to BKVN [28] . Frequent monthly BKV monitoring and pre-emptive reduction of immunosuppression have been shown to be beneficial in reducing the risk of BKVN occurring. This strategy is effective in improving overall graft outcomes in renal transplant recipients as there is no definitive medical therapy for BKVN with graft failure still occurring. However, this approach may be cost prohibitive for those resource restricted centres especially where a low incidence of BKVN is identified [29] . Screening for decoy cells in the urine first may be a cheaper option [33] , but there is a high prevalence rate of BK viruria even in immunocompetent adults and not all centres have resources to perform this test. Though cost saving can be achieved by reductions of immunosuppression as described in the literature [38, 39] , they may not necessarily cover the cost of screening for BKV if immunosup pressants are inexpensive. To reduce the financial burden by increasing the monitoring interval to every 3 mo or longer, it may not reduce the incidence of BKVN as seen in the other studies. Nevertheless, either screening approach may not necessarily preserve graft function for those with BKVN. It is also interesting to see that the group with unknown BKV status in this cohort had a similar median eGFR comparing to those without BK viraemia, thus questioning the necessity of screening in this context. Our study is likely underpowered and increasing differences among these groups would likely have been observed in a large sample size. Targeting only those recipients who have significant predisposing risk factors could potentially reduce screening cost, but there is no consistency in what these risk factors are in the literature, thereby failing to identify BKVN cases early. Another cost saving option would be to identify recipients with positive BK viraemia early by performing an intensive monthly BKV screening only in the first 3 mo of renal transplant when the degree of immunosuppression is the greatest followed by a 3 mo screening until 12 mo after transplant. Therefore, when designing a BKV surveillance programme, it should be centre specific by taking the epidemiology of BKV infection, immunosuppression and monitoring protocols and related costs in a transplant centre into consideration to make it viable and cost effective.
There are several limitations in this retrospective study. Due to the lack of a comprehensive screening program we may have underestimated the incidence of BKVN. With our current approach of undertaking renal biopsy in all patients with a significant decline in renal function, it is unlikely that there are many patients with clinically significant BKVN that are not recognised. Interestingly, three patients with BKVLs of more than 160000 copies/mL did not have transplant biopsies due to stable graft function. Because of the selected cohort, the sizes of the comparative groups were small and there were only 9 recipients with BKVN which allow only a small number of variables to be included in the multivariable Cox regression model. As a result, the study is likely underpowered. In addition, there might be other risk factors for BKVN that were not identified, and tacrolimus and ciclosporin levels were not included in this study. Due to a large number of the recipients not tested for BKV, we cannot make effective comparisons, evaluate risk factors for BK viraemia or perform a cost analysis in this cohort.
A comprehensive BK virus surveillance program and reduction of immunosuppressive therapy is the reco gnised management strategy to reduce the risk of BKVN occurring, because BKVN significantly impairs graft function. This study highlights that in our cohort the incidence of BKVN and graft failure due to BKVN without a formal screening programme is low and comparable to some transplant centres that have a BKV surveillance programme. Long CIT is associated with BKVN. The risk factor for BKVN identified is not consistent with other studies suggesting intricacy in the pathogenesis of BKVN and different protocols adopted by various transplant centres. Though the outcomes of this study remain speculative particularly the incidence of BKVN due to the study's limitations and it requires further validation in larger trials, it provides a similar perspective in BK virus screening to Kiberd's and Smith's studies [29, 38] . Transplant centres should evaluate its immunosuppression and monitoring protocols, the epidemiology of BKV infection and related costs before designing a BKV surveillance programme to make it centre specific and cost effective.
COMMENTS
Background
Screening for BK viraemia is an important strategy in reducing the risk of BK polyomavirus nephropathy (BKVN) and requires monthly monitoring in the first year of transplant in order for a BK virus surveillance to be effective. Applying this surveillance strategy in any transplant centres may not necessarily produce the best possible outcomes due to resource constraints and a low incidence of BK virus infection. This retrospective study was performed to compare outcomes of BK virus infection in the Auckland region without a formal BK virus screening program with those in centres with a BK virus surveillance program reported in literature.
Research frontiers
There are many risk factors, such as immunosuppressive burden, human leukocyte antigen mismatch, implicated in BK virus infection and the development of BKVN in renal transplant recipients. Therefore, immunosuppression and monitoring protocols play a role in BK virus infection. When designing a surveillance program for BK virus, the authors feel that immunosuppression and monitoring protocols, the epidemiology of BK virus infection and related costs should also be evaluated.
Innovations and breakthroughs
Outcomes of BKV infection, particularly BKVN, in this studied cohort are similar to some of transplant centres with a formal BK screening program that has less frequent testing for BKV.
Applications
Screening for BKV infection is important. Some transplant centres with limited resources may not afford frequent BKV testing or have capacity to perform BKV test. The study results suggest that a BKV screening program should be centre specific to be cost effective and achieve best possible outcomes.
Peer-review
This retrospective study looked at the incidence of BK viremia, BK nephropathy and graft outcomes among kidney transplant recipients in Auckland region. Study is well conducted and written clearly.
